Literature DB >> 458145

The alternative pathway C3/C5 convertase: chemical basis of factor B activation.

P H Lesavre, T E Hugli, A F Esser, H J Müller-Eberhard.   

Abstract

The structural basis of activation of the alternative pathway C3 convertase was explored. For this purpose a modified isolation procedure of the activating enzyme, Factor D, was elaborated. The procedure affords a 70,000-fold purification of the enzyme with a 20% yield. A simple assay was designed for the quantitation of both Factor D and Factor B activity. On the basis of activity measurements and amino acid analysis, Factor D concentration in plasma was estimated to be 1 microgram/ml. Highly purified Factor D was used to activate Factor B in the presence of C3b and Mg++. The resulting fragments, Ba and Bb, were characterized with respect to their circular dichroism spectra, amino acid compositions, reactive sulfhydryl groups, and partial amino- and carboxy-terminal sequences. The results indicate that the Ba fragment constitutes the amino-terminal region and the Bb fragment the carboxy-terminal region of Factor B. The bond in Factor B that is cleaved by Factor D is proposed to be an arginyl-lysine bond.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458145

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein.

Authors:  Takayuki Fujita; Takayuki Fujioka; Tetsuo Murakami; Atsushi Satomura; Yoshinobu Fuke; Koichi Matsumoto
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  Ail provides multiple mechanisms of serum resistance to Yersinia pestis.

Authors:  Joshua J Thomson; Sarah C Plecha; Eric S Krukonis
Journal:  Mol Microbiol       Date:  2018-10-26       Impact factor: 3.501

4.  Fragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammation.

Authors:  Edi Vaisbuch; Roberto Romero; Offer Erez; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Kusanovic Juan Pedro; Eleazar Soto; Francesca Gotsch; Zhong Dong; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Pooja Mittal; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-10

5.  The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.

Authors:  M A Kerr; C Parkes
Journal:  Biochem J       Date:  1984-04-15       Impact factor: 3.857

6.  New synthetic inhibitor to the alternative complement pathway.

Authors:  N Ikari; Y Sakai; Y Hitomi; S Fujii
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

7.  The reaction of iodine and thiol-blocking reagents with human complement components C2 and factor B. Purification and N-terminal amino acid sequence of a peptide from C2a containing a free thiol group.

Authors:  C Parkes; J Gagnon; M A Kerr
Journal:  Biochem J       Date:  1983-07-01       Impact factor: 3.857

8.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

9.  Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation.

Authors:  A Sahu; T R Kozel; M K Pangburn
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

10.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.